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ABSTRACT
The influenza A virus (IAV) is a continuous health
threat to humans as well as animals due to its recur-
ring epidemics and pandemics. The IAV genome is
segmented and the eight negative-sense viral RNAs
(vRNAs) are transcribed into positive sense comple-
mentary RNAs (cRNAs) and viral messenger RNAs
(mRNAs) inside infected host cells. A role for the
secondary structure of IAV mRNAs has been hypoth-
esized and debated for many years, but knowledge
on the structure mRNAs adopt in vivo is currently
missing. Here we solve, for the first time, the in vivo
secondary structure of IAV mRNAs in living infected
cells. We demonstrate that, compared to the in vitro
refolded structure, in vivo IAV mRNAs are less struc-
tured but exhibit specific locally stable elements.
Moreover, we show that the targeted disruption of
these high-confidence structured domains results in
an extraordinary attenuation of IAV replicative capac-
ity. Collectively, our data provide the first comprehen-
sive map of the in vivo structural landscape of IAV
mRNAs, hence providing the means for the develop-
ment of new RNA-targeted antivirals.
INTRODUCTION
Influenza A virus (IAV) represents a considerable public
health threat due to its epidemic, pandemic, and zoonotic
potential, causing high costs every year (1), exemplified by
the tragic ”Spanish” flu in 1918 which led to the death of
millions of people (2). According to theWorldHealthOrga-
nization (WHO), annual influenza epidemics cause world-
wide 3–5 million cases of severe disease and up to half
million deaths among high-risk groups, such as children,
elderly and immunocompromised patients, with an even
greater impact in developing countries. IAV belongs to the
Orthomyxoviridae family and is a negative sense, single-
stranded RNA virus. Its genome is organized into eight seg-
ments, thereby allowing for reassortment when coinfection
of a host cell with different IAV subtypes occurs (3), further
leading to the need for development of ever new potent an-
tiviral agents. IAV forms three different RNA species dur-
ing its life cycle in infected cells, namely the genomic minus
sense viral RNAs (vRNAs), the plus sense complementary
RNAs (cRNAs), serving as templates to replicate the viral
genome, and the plus sense viral messenger RNAs (mR-
NAs) (4). The vRNAs, as well as the cRNAs, are covered
with viral nucleoprotein (NP) (5,6). Within viral particles,
vRNAs are associated with the viral polymerase (consisting
of PA, PB1, PB2) via the panhandle structure (which poises
them to be transcribed as soon as they enter the nucleus of
the host cell) to form the viral ribonucleoproteins (vRNP)
complexes (5). The correct packaging of all eight segments
into one viral particle is believed to be conferred at least
in part via structured RNA domains of vRNAs protruding
from vRNPs (7–9).
RNA structure probing techniques coupled to high-
throughput sequencing allow detection of structural fea-
tures of RNA molecules transcriptome-wide (10). These
methods provide the means to understand the previously
underappreciated role RNA structure plays in the com-
plex cellular environment. The impact that RNA structure
has on regulating and fine-tuning cellular processes became
particularly relevant with the extension of transcriptome-
scale structure probing approaches to in vivo applications
(11–20). Furthermore, development of mutational profiling
(MaP) increased the feasibility of RNA structure probing
approaches to address relevant biological questions by in-
creasing coverage across transcripts due to read-through at
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probing sites, thereby omitting the need for size-selection of
truncated cDNA fragments (18,21,22).
Recently, in vivo RNA secondary structures have further
been described in the context of their specific functionali-
ties (23–25). Zhang et al. described how mRNA structure
is essential to regulate acclimation during cold shock in
bacteria which is mainly regulated via Csp proteins, whose
translation is in turn regulated by a structural switch in
their 5′-UTRs. Beaudoin et al. revealed that RNA structure
is dynamically regulated during development in zebrafish
and showed especially 3′-UTRs to be of great importance
as structures therein regulate miRNA accessibility. These
studies likely mark only the beginning of an increasing re-
search to investigate how RNA structures regulate cellu-
lar processes in greater detail. These intriguing insights fur-
ther hint that RNA viruses likely regulate aspects of their
replicative cycles at least in part via RNA structure.
Ever since the first genome-wide resolution of RNA
structure, whichmodeled the ex virio secondary structure of
the HIV-1 RNA genome (21,26) and the finding of impor-
tant structural elements also in the hepatitis C virus genome
(27), the interest of the scientific community in RNA struc-
ture of viruses is steadily growing. However, sparse is the
knowledge about the structure that IAVmRNAs adopt and
the available studies are limited to in vitro experiments or in
silico predictions (28–40). Mostly, structures are described
in the context of splicing of segments 7 M (M1/M2) and 8
NS (NS1/NEP). For example, Jiang et al. described struc-
tures at splice junctions of IAV segment 7 and 8 and showed
by mutagenesis that these elements are likely functional
(41). It was further shown that antisense nucleotide target-
ing of a structural element in segment 5 (NP) can reduce vi-
ral replication (37). However, other studies on IAVmRNAs,
apart from examining structures in vitro, mainly remain de-
scriptive.
Here, we present the first overview of the structure of
IAVmRNAs in their native in vivo state during infection, as
well as a thorough comparison with its structure under in
vitro conditions. By designing mutations aimed at disrupt-
ing high-confidence structural domains, we show that the
virus relies on these structural elements to promote efficient
viral replication and infectivity. The work demonstrates a
general pipeline for rapid investigation of in vivo structures
for many other RNA viruses (and basically any other RNA
in cells, even with low abundance). Such data has extraordi-
nary potential to be used to design potential RNA-targeted
antivirals.
MATERIALS AND METHODS
Infection of MDCK cells with IAV
Confluent monolayers of MDCK cells (Sigma Aldrich,
#84121903-1VL) in 10 cm cell culture dishes were infected
with Influenza A virus (A/Puerto Rico/8/1934(H1N1)) at
a MOI of 5 in DMEM containing 0.14% BSA and 1 g/ml
TPCK-Trypsin for 6 h at 37◦C. Infected cells were washed
twice with PBS, and harvested by centrifugation at 524 × g
(4◦C) for 5 min. Cell pellets were snap-frozen in liquid ni-
trogen and kept at −80◦C until use.
In vivo dimethyl sulfate (DMS) probing
Cell pellets were resuspended in 1ml ofRNAprobing buffer
(RPB) [50 mMHEPES pH 7.9; 140 mMNaCl; 3 mMKCl]
and pre-equilibrated at 37◦C for 5 min. 1.76 M DMS in
ethanol was added to a final concentration of 200 mM. Af-
ter gentle vortexing, probingwas allowed to proceed at 37◦C
for 2 min with moderate shaking. Reactions were quenched
by addition of DTT to a final concentration of 0.7 M.
Cells were collected at 2000 × g (4◦C) for 3 min and sub-
sequently washed once with PBS/0.7 M DTT. Cells were
collected by centrifugation and total RNA extracted with
TRIzol Reagent (ThermoFisher Scientific, #15596018). Af-
ter phase separation, the aqueous phase was added to 1 ml
of 100% ethanol and the RNA purified on RNA Clean &
Concentrator-5 columns (Zymo Research, #R1016).
DMS-MaPseq on E. coli rRNAs for folding parameters’ cal-
ibration
For rRNA probing under ex vivo deproteinized condi-
tions, a single colony of Escherichia coli K-12 DH10B was
picked and inoculated in LB medium without antibiotics,
then grown to exponential phase (OD600 ∼ 0.5) and 1.5
ml aliquots were collected by centrifugation at 1000 × g
(4◦C) for 5 min. Bacteria were treated identically to IAV-
infected MDCK cells (see above). Deproteinized E. coli
RNAwas prepared essentially as previously described (42).
Briefly, cell pellets were resuspended in 1 ml of resuspension
buffer [15 mM Tris–HCl pH 8.0; 450 mM Sucrose; 8 mM
EDTA], and 18 500 U of Ready-Lyse Lysozyme (Epicentre,
#R1810M) were added. After incubation at 22◦C for 5 min
and on ice for 10 min, protoplasts were collected by cen-
trifugation at 5000 × g (4◦C) for 5 min. Pellets were resus-
pended in 120 l Protoplast Lysis Buffer [50 mM HEPES
pH 8.0; 200 mMNaCl; 5 mMMgCl2; 1.5% SDS]. Samples
were incubated for 5 min at 22◦C and for 5 min on ice, fol-
lowed by addition of 30l SDS precipitation buffer (50mM
HEPES pH 8, 1 M KOAc, 5 mM MgCl2). The precipitate
was removed by centrifugation at 17 000 g (4◦C) for 5 min
and the supernatant was subjected to gel filtration onProbe-
Quant G-50 Micro Columns (GE Healthcare, #28-9034-
08) pre-equilibrated three times with RNA folding buffer
(RFB) [50 mM HEPES pH 8.0; 200 mM KOAc; 5 mM
MgCl2]. The eluate was then extracted two times with phe-
nol:chloroform:isoamyl alcohol (25:24:1, pre-equilibrated
three times with RFB), and once with chloroform. 20 U of
SUPERase In RNase Inhibitor (ThermoFisher Scientific,
#AM2696) were added and RNA equilibrated at 37◦C for
20 min prior to probing with 200 mM DMS for 2 min at
37◦C with moderate shaking. The probing reactions were
then quenched by DTT addition to a final concentration of
0.7 M and RNA extracted with TRIzol.
RNA antisense purification (RAP) of IAV mRNAs
50 g of total RNA from infected and DMS-modified
cells were used for poly(A)-enrichment with Dynabeads
Oligo(dT)25 (Thermo Fisher Scientific, #61002). The iso-
lated poly(A) RNA was used as input for the capture of
IAV mRNAs using biotinylated DNA probes (one probe
for each segment with a length of 80 nt complementary to
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mRNA, for sequences refer to Supplementary Table S1).
100 l of Dynabeads MyOne Streptavidin T1 beads (Ther-
moFisher Scientific, #65601) were washed twice with 500l
Wash Buffer 2 [100 mM NaOH; 50 mM NaCl], twice with
500 l Wash Buffer 3 [100 mM NaCl], and resuspended in
200 l 2× Binding & Wash Buffer 1 [10 mM Tris–HCl pH
7.5; 2 M NaCl; 1 mM EDTA]. 5 l of an equimolar mix
of all eight probes (100 M pool) in 200 l water were de-
natured at 85◦C for 3 min, then immediately placed on ice
and added to the washed beads. Probes were immobilized
on beads for 20 min at 37◦C, with vigorous shaking. Beads
were then washed twice with 500 l 1× Binding & Wash
Buffer 1 and resuspended in 100 l RNA Binding Buffer
[20 mM Tris–HCl pH 7.5; 1 M LiCl; 2 mM EDTA]. To the
poly(A)-enriched RNA in 100 l water, 100 l RNA bind-
ing buffer were added and the sample was denatured at 70◦C
for 5 min and immediately placed on ice. Washed beads,
supplemented with 40 U of SUPERase In RNase Inhibitor,
were then added to the poly(A) RNA and binding was al-
lowed to occur at 37◦C for 2 h, with vigorous shaking. Sam-
ples were washed twice with 1 ml of Wash Buffer A (10 mM
Tris–HCl pH 7.5; 150 mM LiCl; 1 mM EDTA; 0.1% SDS]
and once with 1 ml Wash Buffer B [10 mM Tris–HCl pH
7.5; 150 mM LiCl; 1 mM EDTA]. Beads were resuspended
in 100 l 95% formamide and 10 mM EDTA pH 8.0, and
incubated at 90◦C for 10 min. Eluted IAV mRNA was sep-
arated from the beads and purified with 1 ml of TRIzol. To
remove residual DNA probes, the eluate was treated with
DNase I for 15 min at 37◦C and further purified on RNA
Clean & Concentrator-5 columns.
Library preparation
IAV mRNA was fragmented in 64 mM Tris–HCl pH 8.3,
96 mM KCl, 3.9 mM MgCl2 for 8 min at 94◦C and
subsequently purified on RNA Clean & Concentrator-5
columns. Reverse transcription (RT) was performed using
the TGIRT-III enzyme (InGex, #TGIRT50) as described
previously (18). Briefly, to the 5 l of fragmented RNA, 1
l 10 mMdNTPs and 0.5l 10Mrandom hexamers were
added, and the mixture was heated to 70◦C for 5 min and
immediately placed on ice for 1 min. 2 l of 5X RT Buffer
[250 mM Tris–HCl pH 8.3; 375 mM KCl; 15 mM MgCl2],
DTT to 5 mM, 10 U SUPERase In RNase Inhibitor, and
100 U TGIRT-III were added. Reverse transcription was
then allowed to proceed at 25◦C for 5 min, followed by 1.5
h at 57◦C. To remove TGIRT-III from the RNA–DNA du-
plex, 1l of proteinaseKwas added to a final concentration
of 0.1g/l and the reaction incubated at 37◦C for 15min.,
1 l of a 1:2 dilution of protease inhibitor cocktail (Sigma
Aldrich, #P8340) was then added to inhibit proteinase K
activity. The reaction volume was then adjusted to 25 l by
adding 3l of 5×RTBuffer and 10l water. Libraries were
then prepared using the TruSeq RNA Library Prep Kit v2
(Illumina, #15025063), starting from second strand synthe-
sis.
Denatured control samples
For denatured control samples, RNAwas directly extracted
from infected MDCK cell pellets with TRIzol and viral
(+)RNA was purified from 75 g total RNA using bi-
otinylated probes as stated above, but using 150 l Dyn-
abeads MyOne Streptavidin T1 beads and 7.5 l of a 100
M equimolar probes pool. After DNase I treatment and
fragmentation, samples were treated with DMS after de-
naturation. For that, the RNA was heated to 95◦C for
1 min in a total volume of 90 l with 55 mM HEPES
pH 7.9, 4.4 mM EDTA, 55% formamide. 10 l of 0.5 M
DMS in ethanol were then added to obtain a probing con-
centration of 50 mM. Probing was allowed to proceed at
95◦C for 1 min. Reactions were quenched by adding 200 l
RNA Binding Buffer (from RNA Clean & Concentrator-
5 columns) supplemented with DTT to a final concentra-
tion of 750 mM. Samples were then purified on RNAClean
& Concentrator-5 columns. Libraries were prepared as de-
scribed above (starting from RT).
Targeted DMS-MaPseq of spliced IAV segments 7 and 8
For structure probing of spliced segments 7 and 8, infected
cells were probed in vivo as above using DMS at a final con-
centration of 50 mM. 3 g of extracted total RNA were
subjected to RT as described above with slight modifica-
tions. Reactions were performed in 20 l total reaction vol-
ume. An anchored oligo(dT) primer with overhang for sub-
sequent PCR (Supplementary Table S2) was used at a fi-
nal concentration of 50 M. The RT reaction was allowed
to proceed at 57◦C for 2 h. Afterward, RNA was degraded
by adding 1 l 5 M NaOH and heating to 95◦C for 3 min
and subsequently purified on RNA Clean & Concentrator-
5 columns. Short splice isoforms were then specifically am-
plified via PCR (primer sequences in Supplementary Table
S2) and gel purified. The short splice isoforms were mixed
equimolarly and fragmented by sonication to yield frag-
ments in the range of 100–300 bp. Sonicated DNA was gel
purified to remove residual full-length products and sub-
jected to library preparation using NEBNext ChIP-Seq Li-
brary Prep Master Mix Set for Illumina (New England Bi-
olabs, #E6240L) according to manufacturer’s instructions,
but omitting size selection.
Targeted DMS-MaPseq of probe pairing regions
Despite DNase I treatment of captured IAV mRNA, carry-
over of biotinylated oligonucleotide probes occurred, result-
ing in lower mutation frequencies detected on probe pairing
regions. To account for this, these regions were further in-
terrogated by targeted PCR. To this end, total RNA from
cells probed in vivowith 50mMDMSwas used. RTwas per-
formed as described above, using a 50 M primer mix con-
taining a specific primer for each segment. Primers annealed
directly before the respective probe pairing position and
contained an overhang corresponding to the standard Illu-
mina adapter (Supplementary Table S2). cDNA was PCR-
amplified and the resulting amplicons were pooled equimo-
larly to 1 ng/l. Indexed adapter sequences were further
added by a second PCR enrichment step.
Targeted DMS-MaPseq of mutated domains
To confirm structure disruption in mutant viruses with re-
spect to the wild-type (WT) structure, we interrogated these
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domains by targetedDMS-MaPseq analysis in cells infected
with the respective IAVmutants. MDCK cells were infected
as described above at a MOI of 1. Six hours post-infection,
cells were harvested and probed with DMS at a final con-
centration of 100 mM. RT was performed as for the tar-
geted approaches described above, using 50Mof a specific
primer (except for segment 5 for which an oligodT primer
with an overhang was used, see Supplementary Table S2).
PCR was then performed on the resulting cDNA using
specific primers amplifying a region of ∼250–300 bp cen-
tered on the mutated domains. PCR products were pooled
equimolarly and fragmented by sonication, then libraries
prepared as described above for the short splice isoforms.
In vitro RNA structure probing
The T7 promoter was introduced at the 5′ end of each seg-
ment via PCR using pDZ-PB2, PB1, PA, HA, NP, NA, M,
NS plasmids as a template (for primers utilized see Supple-
mentary Table S2). Segments were then in vitro transcribed
using T7-FlashScribe kit (CellScript, #C-ASF3507). Tran-
scription products were verified by capillary electrophoresis
on a FragmentAnalyzer (AdvancedAnalytical). For in vitro
refolding, segments were pooled equimolarly and 240 ng of
the pool were used per replicate. RNA in 15.3 l was heated
to 95◦C for 2 min and immediately placed on ice for 1 min.
9 l of 3.3× Folding Buffer [333 mM HEPES pH 7.9; 333
mM NaCl] were added and the sample incubated at 37◦C
for 10 min before addition of 2.7 l of 100 mMMgCl2 pre-
warmed to 37◦C, and additional incubation at 37◦C for 20
min. For probing, 1.76MDMS in 100% ethanol was added
to a final concentration of 200 mM and probing allowed to
occur at 37◦C for 2 min, with moderate shaking. Reactions
were quenched by addition of DTT to 0.7 M and purified
on RNA Clean & Concentrator-5 columns. Samples were
fragmented and libraries prepared as described above.
DMS-MaPseq data analysis
All the relevant analysis steps, from reads alignment to data
normalization and structure modeling, were performed us-
ing RNA Framework (43). Briefly, sequencing reads were
clipped from adapter sequences and terminal positions with
Phred qualities <20 were trimmed. Alignment was per-
formed using the rf-map tool and the Bowtie v2 algorithm
(44), with soft-clipping enabled (parameters: -b2 -cp -b5
5 -mp ”–very-sensitive-local”). Before proceeding to DMS-
MaPseq data analysis, sequencing of an untreated IAV sam-
ple was performed in order to annotate eventual mutations
with respect to the reference strain. Positions with muta-
tions exceeding a frequency of 50% were annotated. All the
subsequent analysis steps were then performed using this
updated reference. Per-base mutation count and coverage
were calculated using the rf-count tool (parameters: -nm -r
-m -mq 0 -na -md 3 -ni). A ratiometric score was then calcu-
lated as:
ri = miCi
where ri, mi, and Ci are respectively the raw reactivity, the
mutation count and the coverage at position i. Reactiv-
ity normalization was performed as a 2-step process. First,
each sample (including the denatured control) was normal-
ized by 90% Winsorizing, in order to smooth the contri-
bution of both over and under-reactive residues, using the
rf-norm tool (parameters: -sm 4 -nm 2 -rb AC -n 200). Al-
though median coverage was generally >1000× for each
segment, we nonetheless imposed a minimum coverage of
200× per base, in order to discard lowly covered bases at
segment boundaries. Briefly, each reactivity value above the
95th percentile was set to the 95th percentile and each reac-
tivity value below the 5th percentile was set to the 5th per-
centile, then the reactivity at each position of the transcript
was divided by the value of the 95th percentile. Reactivity
data from targeted DMS-MaPseq analysis of probe pair-
ing regions was independently Winsorized and then used to
replace original RAPiD-MaPseq data. Second, both the in
vitro and the in vivo datasets were normalized to the respec-
tive denatured controls:
Ri = min
(
Si
Di
, 1
)
where Ri, Si, and Di are respectively the normalized re-
activity, the sample reactivity (either in vivo or in vitro),
and the denatured control reactivity at position i. This nor-
malization yielded reactivity values comprised between 0
(low single-strandedness probability) and 1 (high single-
strandedness probability).
Given the high correlation of all the datasets, biological
replicates were combined using the rf-combine utility fol-
lowing normalization. Combined datasets were then used
for all downstream analyses.
Structure modeling
To perform structuremodeling, we first usedDMS-MaPseq
data from deproteinized E. coli rRNAs to determine the
optimal slope and intercept folding parameters. Fine tun-
ing of these parameters allows penalizing (or rewarding) the
formation of certain base-pairs, proportionally to the mea-
sured structural reactivity. This process is performed by pre-
dicting the reference structures (in our case E. coli 16S and
23S rRNAs) with different slope/intercept pairs, until the
pair that gives the highest agreement to the known refer-
ence structure has been identified, a process known as grid
search (or jackknifing). Grid searchwas performed using the
rf-jackknife utility from the RNA Framework package (pa-
rameters: -rp ”-nlp -md 600” -x). Optimal slope and inter-
cept values were determined to be respectively 2.8 and −0.4
kcalmol−1 for the in vivo dataset, and 2.6 and−1 kcalmol−1
for the in vitro dataset.
Structure modeling was performed using the rf-fold util-
ity from the RNA Framework package (which implements
a windowed folding approach similar to the one previously
employed to infer the HIV-1 genome structure (21)), and
theViennaRNAPackage 2.0 (45), using the aforementioned
slope/intercept value pairs (parameters: -g -md 600 -nlp -
w -pw 800 -fw 1000 -pk -km 2 -kw 600 -ko 200 -dp -sh -sl
<slope> -in <intercept>).
Prediction of pseudoknotted base-pairs. During the first
stage, each viral segment was folded in 600 nt sliding win-
dows, slid in 100 nt increments. DMS-MaPseq data was
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incorporated into the prediction, using the previously de-
termined slope/intercept pairs. Three additional folds were
computed at the 5′ and 3′ ends of each segment to increase
sampling of terminal regions. Pseudoknots were required
to occur in >50% of the windows containing the involved
base-pairs, and to have an average DMS reactivity < 0.7 in
order to be retained.
Partition functionmodeling. Partition function foldingwas
calculated for each viral segment in 800 nt sliding windows,
slid in 200 nt increments. The maximum base-pairing dis-
tance was set to 500 nt. DMS-MaPseq data was incorpo-
rated into the prediction, using the previously determined
slope/intercept pairs. Three additional folds were computed
at the 5′ and 3′ ends of each segment to increase sampling
of terminal regions. 100 nt were trimmed from both ends
of each window to avoid terminal biases. Base-pairs with
>0.99 probability of formation were retained. During this
stage, the Shannon entropy at each position of the transcript
was calculated as:
Si = −
J∑
j = 1
pi, j log10 pi, j
where Si and pi,j are respectively the Shannon entropy at
position i of the transcript and the probability of i being
base-paired with j (with j ∈ J, where J is the set of all the
potential pairing partners of i).
Minimum free energy modeling. Minimum free energy
folding was performed for each viral segment in 1000 nt
sliding windows, slid in 200 nt increments. The maximum
base-pairing distance was set to 500 nt. DMS-MaPseq data
was incorporated into the prediction, using the previously
determined slope/intercept pairs. Base-pairs retained dur-
ing the two previous stages were incorporated as hard-
constraints in the prediction. Five additional folds were
computed at the 5′ and 3′ ends of each segment to increase
sampling of terminal regions. Base-pairs present in more
than 50%of the windows in which they could have appeared
were retained, yielding the final Minimum Expected Accu-
racy structure (MEA). Structure models were plotted using
VARNA (46).
Assessing conservation of helices
To assess helices’ conservation, we obtained all the full-
length sequences available in the NCBI Influenza Virus
Database (https://www.ncbi.nlm.nih.gov/genomes/FLU/).
This resulted in a total of: 14,276 sequences for segment
1, PB2 (5,050 from H1N1/H5N1); 14,619 sequences
for segment 2, PB1 (5,088 from H1N1/H5N1); 14,617
sequences for segment 3, PA (5,172 from H1N1/H5N1);
11,507 sequences for segment 4, HA (3,798 from
H1N1/H5N1); 13,253 sequences for segment 5, NP
(4,630 from H1N1/H5N1); 23,773 sequences for segment
6, NA (9,243 from H1N1/H5N1); 12,514 sequences for
segment 7, M (4,371 from H1N1/H5N1); and 29,272
sequences for segment 8, NS (11,834 from H1N1/H5N1).
Identical sequences were collapsed. From each sequence,
the untranslated regions (UTRs) and the coding sequences
(CDS) were extracted and independently aligned using
different approaches. UTRs were aligned using the Clustal
Omega algorithm (47). CDSs were first translated, aligned
using theMuscle algorithm (48) and then converted back to
nucleotides. UTR/CDS alignments were then chained. For
each predicted base-pair in our MEA structure, we then
calculated a conservation frequency by counting the num-
ber of sequences in which the base-pair was maintained,
divided by the total number of aligned sequences.
Ranking of IAV RNA structural motifs
In order to prioritize IAV mRNA structural motifs more
likely to have an impact on the fitness of IAV, we empirically
devised a scoring scheme that rewarded more those motifs
having: (i) high probability of formation (low Shannon en-
tropy) both in vivo and in vitro, (ii) high conservation and
(iii) long helices (larger domains). A score was calculated
for each motif according to the formula:
S= Pin vivo · Pin vi tro · C · log2
(
L
2
)
where S, Pin vivo, Pin vitro, C and L are respectively the score,
the in vivo and in vitro formation probabilities, the conser-
vation and the number of base-pairs of the structural mo-
tif. Multi-branched loops were split into their individual he-
lix components and evaluated separately. For each segment,
the top-scoring motif was selected for further validation.
Design of structure-disrupting mutants
To design structure-disrupting mutants that did not alter
the underlying amino acid sequence, we developed a tool
that iteratively replaced each codon within a given RNA
structural motif with synonymous codons (avoiding rare
codons). Amaximum of three codons were allowed to be si-
multaneously mutated. If the motif was predicted to be part
of a larger domain in vitro, mutations were also allowed to
occur on ±10 nt surrounding the motif. After each muta-
tion, the algorithm evaluated the base-pairing distance be-
tween the mutated andWT structures, as well as the proba-
bility of still observing the WT structure in the Boltzmann
ensemble. The set ofmutationsmaximizing the base-pairing
distance andminimizing the probability of formation of the
WT structure was chosen. This tool will be introduced in
the next RNA Framework release. Positions of introduced
mutations have been detailed in Supplementary Table S5.
Recombinant IAV production
Bidirectional pDZ plasmids containing the respective mu-
tated viral segments were produced using QuikChange XL
Site-Directed Mutagenesis Kit (Agilent, #200516-5) in up
to three successive rounds of mutagenesis. To this end,
segments were first sub-cloned into pCR-Blunt II-TOPO
(ThermoFisher Scientific, #K280002) using the KpnI re-
striction enzyme, in order to facilitate mutagenesis (pDZ
plasmid is very GC-rich). After mutagenesis, segment se-
quences were checked by Sanger sequencing. Mutated seg-
ments were cloned back into the KpnI-digested pDZ plas-
mid and the correct orientation of the inserts was confirmed
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by PCR screening. Mutant IAVs were produced essen-
tially as previously described (49), with slight modifications.
Briefly, co-cultures of 5 × 105 MDCK and 5 × 105 HEK
293FT (ThermoFisher Scientific, #R70007) cells per well
(six-well plate format) were plated the day before transfec-
tion. 1 g of each pDZ plasmid was transfected using Lipo-
fectamine 2000 (ThermoFisher Scientific, # 11668027). Af-
ter 16–24 h, transfection medium was changed to viral in-
fectionmedium (VIM) [DMEM; 1%PenStrep; 0.3%BSA; 1
g/ml TPCK-trypsin (Sigma, #T-1426)]. 48 h after chang-
ing the medium, the tissue culture supernatants were cen-
trifuged at 17 000 × g (room temperature) for 1 min and
500 l of supernatant were used to infect 1 × 106 MDCK
cells (six-well plate format). Cells were then incubated for
48 or 72 h in VIM, until a cytopathic effect was observed.
Viruses were then plaque purified and the viral titers were
determined by plaque assay (see below).
Plaque assay
Confluent monolayers ofMDCK cells (2.4× 105 cells/well,
24-well plate format, triplicate) were seeded the day prior
to infection. For each virus assayed, 10-fold serial dilutions
(10−3 to 10−6) were prepared. Every dilution was assayed
in triplicate. For infection, cells were washed twice with
PBS and 150 l of each viral dilution were added. Viral
absorption was allowed to occur for 1 h at 37◦C, vascu-
lating the plate every 12 min. After viral absorption, cells
were overlaid with 750 l VIM with a final concentration
of 0.7% Avicel RC 581 (FMC BioPolymer). Infection was
allowed to proceed for 2 days at 37◦C. Subsequently, cells
were fixed for 1 h at room temperature by adding 500 l of
4% paraformaldehyde. The supernatant was then removed
and cells stained for 40 min with 1% crystal violet in PBS.
Crystal violet was removed and cells carefully washed with
water. Plaques were counted and PFU/ml were calculated.
IAV multi-cycle growth kinetics
Virus multi-cycle growth kinetics were determined essen-
tially as described (41). Briefly, confluent monolayers of
MDCKcells (3.5× 105 cells/well, 12-well plate format, trip-
licate) were infectedwith the respective IAV (WTormutant)
at a MOI 1 × 10−4. Viral absorption was allowed to occur
at 37◦C in VIM for 1 h, vasculating every 12 min. After-
ward, cells were washed once with PBS and overlaid with
800 l VIM. The infection was allowed to proceed for 14
h, whereupon the supernatant was cleared by centrifuga-
tion at 17,000 × g (at room temperature) for 1 min. The su-
pernatant was then subjected to plaque assay as described
above to determine PFU/ml. P-values were calculated by
Welch’s t-test statistics.
IAV in vitro evolution
Confluent monolayers ofMDCK cells (3.5× 105 cells/well,
12-well plate format) were infected with the respective IAV
(WT or mutants) at aMOI of 0.1 on day 1. Viral absorption
was allowed to occur at 37◦C in VIM for 1 h, vasculating ev-
ery 12 min. Afterward, respective IAVs were removed and
cells were overlaid with 800l VIM. Every 24 h 220l of su-
pernatantwere used to infect new confluentMDCKcells for
a total of 12 passages. An aliquot of supernatant was saved
at each passage and viral RNA was extracted in TRIzol.
For analysis of mutations, extracted RNA from passages 0,
6 and 12 was reverse transcribed with Superscript II accord-
ing to manufacturer’s instructions (Invitrogen, #18064) us-
ing specific primers for the mutated domains (2 primers per
segment were used to amplify (+) as well as (–) sense RNA
of IAV) and domains were then specifically PCR amplified
(see Supplementary Table S2 for primer sequences). PCR
products were used for library preparation analogously to
short splice isoforms.
RESULTS
RAPiD-MaPseq enables targeted in vivo RNA structure
mapping of low-abundance IAV mRNAs
To investigate IAV mRNA structures in the context of in-
fected cells, we here developed RNA antisense purification
combined with dimethyl sulfate (DMS) mutational profil-
ing (RAPiD-MaPseq), an approach that couples in vivo
DMS probing with consecutive oligo-dT and biotinylated
antisense oligonucleotide-mediated capture of target mR-
NAs, thus exploiting the high affinity and specificity of
the biotin-streptavidin interaction to achieve over 13-fold
enrichment of IAV mRNAs (Supplementary Figure S1A).
DMS is an alkylating reagent, able to readily permeate cell
membranes and modify unpaired A and C residues with
fast kinetics (10). This approach provides the unique op-
portunity of allowing to investigate the secondary structure
of low-abundance RNA species in living cells. Thus, we ex-
ploited RAPiD-MaPseq to query the structure adopted by
InfluenzaA/PuertoRico/8/1934(H1N1) IAVmRNAs dur-
ing infection of living cells (Figure 1A). We further gener-
ated an in vitro dataset by in vitro transcription and refold-
ing, in order to both identify thermodynamically favored
RNA structuralmotifs and characterize IAVmRNAs struc-
tural differences between in vivo and in vitro conditions. As it
has been previously shown that context-specific biases exist
and that not all residues have the same propensity to react
with DMS (12), a denatured control sample was also ob-
tained by treating IAV mRNAs with DMS under denatur-
ing conditions, hence providing a measure of the maximum
possible reactivity for each residue (Figure 1B).
Two additional datasets were generated. To account for
the eventual carryover of RAP capture probes, often caus-
ing lower mutation frequencies on probe pairing regions of
IAV mRNAs, structural signal on these regions was further
measured by targeted DMS-MaPseq (Supplementary Fig-
ure S1B). Moreover, as IAV segments 7 and 8 are known
to undergo at least one alternative splicing event (resulting
in two shorter splice isoforms), we specifically interrogated
these shorter variants by targeted DMS-MaPseq analysis.
Successful isolation of IAV mRNAs was confirmed by
the drop of sequencing coverage observed right before the
poly(U) stretches used by the viral RNA-dependent RNA
polymerase complex as a template for the synthesis of
poly(A) tails of IAV mRNAs (Supplementary Figure S1C).
Reverse transcription of the DMS-modified RNA was car-
ried out using the TGIRT-III reverse transcriptase, which is
able to read through DMS alkylated residues with high ef-
ficiency (18). Accordingly, between 86% and 92% of the de-
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Figure 1. Summary of experimental conditions and data normalization. (A) Schematic of the experimental workflow. (B) SampleDMS-MaPseq reactivities
from a hairpin-forming region of IAV segment 8, NS (nt 409–435). The two halves of the helix (indicated by dashed lines) have lower DMS reactivities
compared to the loop region. (C) Heatmap of pairwise Pearson correlations for all IAV DMS-MaPseq datasets. Significant correlations (P-value < 0.05)
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tected mutation events were on A/C residues (Supplemen-
tary Figure S1D). Each condition was assayed in biologi-
cal duplicate (roughly 2 months apart), yielding exception-
ally high correlations (Figure 1C and Supplementary Fig-
ure S10A). Notably, while the in vitro and the denatured
control samples slightly but significantly anticorrelated (av-
erage PCC = −0.07, Edgington-combined FDR-adjusted
P-value = 3.3e–6), a moderate yet highly significant corre-
lation was instead detected between the in vivo and the de-
natured control samples (average PCC = 0.18, Edgington-
combined FDR-adjusted P-value< 2.2e–16). This suggests
that, on average, IAV mRNAs are much less structured un-
der in vivo conditions than they are in vitro. This was fur-
ther confirmed by inspection of base reactivity distributions
(Figure 1D), revealing how the median reactivity of IAV
mRNAs in vivo (0.63) is closer to that of the denatured con-
trols (0.69 and 0.68 respectively for the in vitro and in vivo
denatured samples), than to that of the in vitro refolded sam-
ple (0.49).
Structure modeling of in vivo IAV mRNA structures
To chart accurate experimentally-informed RNA sec-
ondary structure models of IAV mRNAs we next sought
to incorporate DMS reactivities as soft constraints to guide
thermodynamics-based RNA structure inference software
(see Materials and Methods). This approach has been ex-
tensively validated (42,50–52), and previously applied to
successfully infer viral RNA structures under both in vitro
and ex virio conditions (21,26,27,53,54).
Instrumental to a successful chemical probing-guided
modeling of RNA structures is the identification of op-
timal folding parameters (slope and intercept) that are
needed to convert base reactivities into pseudo-free en-
ergy contributions (42,50). In order to identify the op-
timal slope/intercept pairs under our experimental con-
ditions, complementary DMS-MaPseq datasets were pro-
duced by probing E. coli rRNAs under either ex vivo de-
proteinized, in vitro, or denaturing conditions (Supplemen-
tary Figure S2A). Compared to traditional DMS-seq and
DMS-MaPseq data analyses, we here introduced a two-step
normalization process, by first independently normalizing
each dataset by 90% Winsorizing, followed by the normal-
ization of both the in vitro and in vivo datasets onto the de-
natured control sample. This approach allowed us to both
smooth the effect of under and over-reactive residues, and
to increase the signal-to-noise ratio by accounting for the
maximum background probability of each residue to re-
act with DMS (Figure 1E and Supplementary Figure S2B–
D). As a proof of its effectiveness, this 2-step normaliza-
tion approach had negligible effects on base-paired residues
(90%Winsorizingmedian reactivity: 0.04; two-step normal-
ization median reactivity: 0.05), while it strongly increased
the signal on unpaired residues (90% Winsorizing median
reactivity: 0.53; two-step normalization median reactivity:
0.9). Under these conditions, grid search found optimal
slope/intercept value pairs to be respectively 2.8 kcal mol−1
and −0.4 kcal mol−1 for the in vivo dataset, and 2.6 and −1
kcal mol−1 for the in vitro dataset (Supplementary Figure
S2E and F, see Materials and Methods).
By incorporating the identified folding parameters into
DMS-directed structure modeling, we here obtained the
first high-quality single-base resolution secondary structure
maps of the entire IAV transcriptome (nearly 13 500 nt,
across 8 segments, 10 transcripts), under both in vivo and
in vitro conditions (Figure 2 and Supplementary Figures
S3–S18), with a median coverage of at least 6000× in each
dataset. Besides performing minimum free energy (MFE)
folding, partition function folding allowed us to calculate
base-pairing probabilities and to infer per-base Shannon
entropies. Shannon entropy can be used as a proxy to mea-
sure the likelihood of RNA regions to either form a single
stable (low entropy) or multiple alternative (high entropy)
structures (21).
IAV mRNAs are largely unfolded in vivo, but retain crucial
structured domains
Initial model-free inspection of our data through the Gini
index (12,13) that quantifies the evenness of the distribu-
tion of DMS base reactivities, confirmed that IAV mRNAs
are significantly less folded in vivo than in vitro (Supplemen-
tary Figure S19A). Accordingly, structure modeling con-
firmed that, on average, 80.3% of the IAV transcriptome
is unfolded in vivo (Supplementary Figure S19B). This re-
duced propensity to fold into stable secondary structures is
not due to sequence constraints leading to a limited fold-
ing space, as nearly half of the IAV transcriptome is in-
stead stably folded in vitro, similarly to what is expected
for structural RNAs (47.8% on average for mouse 18S/28S
rRNAs). Rather, it is possibly the consequence of an ac-
tive translation-mediated unfolding of RNA structures, as
it has been recently reported for cellular mRNAs (12,24).
Nonetheless, our analysis revealed the presence of a few per-
sistent RNA structural motifs in IAVmRNAs in vivo. These
structures mostly represent locally stable secondary struc-
tures, involving short-range base-pairs (average/median bp
span: ∼49/17 nt). In contrast, larger structures form in
vitro, often involving much longer base-pair interactions
(average/median bp span: ∼75/31 nt, Supplementary Fig-
ure S19C). Roughly 55% of the base-pairs of the in vivomo-
tifs were also predicted to occur in vitro. Conversely, only
23% of the base-pairs formed in vitrowere vice versa present
in vivo (Supplementary Figure S19D). The highest overall
base-pairing conservation between in vivo and in vitro fold-
ings was observed for segments 7 and 8 IAV mRNAs (re-
spectively∼67% and∼75% of the base-pairs present in vivo
were also present in vitro), while the lowest was observed
←−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−
are denoted by a star in the upper-right corner. (D) Violin plot of normalized (90%Winsorizing) DMS reactivities across IAV transcriptome. The median
of each distribution is indicated. (E) (left) Snapshot of 90% Winsorizing and 2-step normalized DMS reactivities on the first 550 nt of E. coli 16S rRNA
under both denaturing and native deproteinized ex vivo conditions. (right) 2-step normalized DMS reactivities superimposed onto the phylogenetic-derived
secondary structure of the E. coli 16S rRNA. The inlay shows superimposition of 90% Winsorizing-normalized reactivity values of the boxed domain for
comparison.
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Figure 2. Transcriptome-wide in vivo secondary structure model of IAV mRNAs. In vivo and in vitro DMS reactivities, reactivity difference (DMS),
Shannon entropies, base-pairing probabilities, minimum expected accuracy (MEA) structure, and helix models with superimposed in vivoDMS reactivities
for IAV segment 8, NS (NS1/NEP). Reactivity values are reported as the arithmetic mean of two biological replicates. Error bars represent SDs. Base-
pairs are depicted as arcs, colored according to their probabilities. Green arcs correspond to base-pairs with P ≥ 0.7. Black dashed arcs correspond to
pseudoknots. Regions with multiple overlapping arcs (high Shannon entropies) correspond to regions that are likely to form alternative structures. Base-
pairs in the MEA structure are depicted as arcs, colored according to their conservation as determined by multi-sequence alignment of IAV mRNAs.
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for segment 4 IAV mRNA (only ∼32% of the base-pairs
present in vivowere also present in vitro). These observations
suggest that, while thermodynamics acts as a major driving
force on the folding of segments 7 and 8 IAVmRNAs, other
cellular factors might be involved in regulating the folding
of segment 4 IAV mRNA. Pseudoknots were predicted for
segments 1, 3, 4, 5 and 8 under in vitro conditions, while no
pseudoknot was predicted to occur in vivo.
Knowledge of IAV RNA structure is very sparse, with
most available data limited to in vitro probing and in sil-
ico predictions, particularly of segments 7 and 8 IAV mR-
NAs. Structural information is missing for most other seg-
ments (Supplementary Figure S20). By systematically an-
alyzing all the 19 literature-available structure models, we
found that respectively, 13 (68.4%) or 9 (∼47.3%) were sup-
ported at different extents either by our in vitro or in vivo
data (Supplementary Figure S21). Most discrepancies can
be easily explained by the fact that a large fraction of these
structures was derived by in vitro probing of a small por-
tion of the underlying IAV segment, outside of its natural
context. In the context of the full segment, instead, they are
usually part of larger domains, thus leading to completely
different foldings in vitro, while they are mostly unfolded
in vivo. Moreover, our structural data comes from probing
of whole cells. We can’t rule out the possibility that certain
structural elements involved in segments 7 and 8 splicing
might form different structures between the nucleus and the
cytoplasm.
We further exploited targeted DMS-MaPseq analysis to
query, for the first time, the structure of the two short iso-
forms produced by the alternative splicing of segments 7
and 8 IAV mRNAs (Supplementary Figure S10), which
yield the matrix 2 (M2) proton channel and nuclear export
protein (NEP), respectively. These two isoforms are mostly
unfolded compared to their full-length counterparts (Sup-
plementary Figure S10B), but respectively retain 3 (nt 894–
919, 950–964 and 967–994) and 2 (nt 562–581 and 603–630)
hairpins of the full-length segments 7 and 8 (Supplementary
Figure S10C and D). Interestingly, splicing of segment 7 re-
sults in the formation of an additional hairpin (nt 51–75 of
the splice isoform) crossing the splice junction.
Loss of conserved thermodynamically-favored structural mo-
tifs potently affects IAV fitness
To investigate whether the identified structural motifs have
a biological role in the context of IAV replication, we next
performed targeted mutagenesis aimed at disrupting these
structures without affecting the underlying amino acid se-
quence. To prioritize the candidate structures most likely to
be functional, we devised an empirical scoring function that
weights more larger motifs (longer helices), with a higher
probability of occurring under both in vivo and in vitro con-
ditions (low Shannon entropies). Structures that are present
both in vivo and in vitro are likely to be strongly thermody-
namically favored. Furthermore, although sequence varia-
tion between IAV strains is too low to allow structure in-
ference by covariation analysis (as confirmed by the anal-
ysis of multiple aligned IAV strain mRNA sequences us-
ing a recently published method aimed at statistically quan-
tifying the evidence for structure conservation (55), data
not shown), we reasoned that including base-pairing con-
servation in our score would at least penalize those RNA
structural motifs that were not under strong purifying se-
lection. Evaluating the conservation of IAV mRNA helices
on a multiple sequence alignment of all available IAV sub-
types (Supplementary Table S3), or restricting the analysis
only to the H1N1 and H5N1 subtypes (Supplementary Ta-
ble S4), only marginally altered the ranking of helices, but
did not alter the top-ranking motifs. The top-ranking struc-
tural motif from each segment was then further selected for
functional validation (highlighted in grey boxes in Figure
2 and Supplementary Figures S3–S9). However, we omit-
ted the top-ranking structure from segment 8 and the splic-
ing junction-crossing structural element in the short iso-
form of segment 7 IAVmRNA from our analysis, due to the
difficulties connected with designing structure-disrupting
mutations without affecting the underlying amino acid se-
quence of both encoded proteins.Mutants were designed by
changing a maximum of three codons concurrently, with-
out altering the encoded amino acid sequence and avoiding
the introduction of rare codons. The mutant which maxi-
mized the predicted base-pair distance from the WT struc-
ture and minimized the frequency of the WT structure in
the Boltzmann ensemble was selected (Figure 3A and Sup-
plementary Figure S22). WT and mutant viruses bearing
mutations that lead to disruption of IAV mRNAs 1 to 7
secondary structures were produced using a previously re-
ported reverse genetics approach (49), and efficient struc-
tural disruption of the target motif was monitored by tar-
geted DMS-MaPseq analysis (Figure 3B and Supplemen-
tary Figure S23). Although the extent of the observed struc-
tural alterations for the designedmutants was unpredictable
solely from in silico prediction, as it ranged from a simple
structural switch (e.g. segment 4), to complete unfolding of
the target motif (e.g. segment 1), we were able to experimen-
tally confirm the efficient disruption of all selected motifs.
Strikingly, multi-cycle growth kinetics of WT and mutant
viruses showed significantly attenuated replication kinetics
at 14 h post-infection for mutated segments 1 to 6, ranging
from 4 to 223-fold compared to WT IAV (Figure 3C). Sur-
prisingly, we did not observe any significant effect for seg-
ment 7 mutant. Even though it is possible that this specific
structural domain might not be essential for the efficient
replication of IAV, a deeper inspection of DMS reactivities
for this mutant revealed that the majority of bases undergo-
ing a structural switch were shifting towards intermediate
reactivity values, coherently with the presence of alterna-
tive RNA conformations. Hence, we can speculate that the
introduced mutations might not be sufficient to completely
abrogate theWT structure from the ensemble, thus resulting
only in a moderate destabilization.
Loss of segment 4 (HA) mRNA top-ranking structural motif
is under strong negative selection
We further hypothesized that, if the targeted disruption of
these domains significantly affects the structural integrity
of the IAV transcriptome, then a strong negative selection
will be observed after several passages of infection, given
the high mutation rate of RNA viruses (56). To this end,
MDCK cells were infected with either WT or mutant IAVs,
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Figure 3. Targeted disruption of top-ranking IAVmRNA structural motifs potently affects viral fitness. (A) In silico design of a structure-disruptingmutant
for IAV segment 4 (HA). Each circle corresponds to a different structure within the Boltzmann ensemble. The diameter of each circle corresponds to the
log2 of the relative abundance of the respective structure within the ensemble. Free energies at 37◦C and base-pair distances were computed in the absence of
any experimental constraint; thus, the predicted structure might slightly differ from the experimentally-determined structure. (B) Targeted DMS-MaPseq
analysis of the mutated top-ranking RNA structural motif for segment 4, HA (nt 1607–1670). 90% Winsorizing-normalized reactivities are reported and
superimposed on both the WT and on the expected mutant structures. (C) IAV multi-cycle growth kinetics. MDCK cell monolayers were infected with
WT or mutant IAVs at a MOI of 10−4. At 14 h post-infection, supernatants were harvested and viral titers determined by plaque assay. P-values are given
by Welch’s t-test statistics. Error bars correspond to SEs from three biological replicates.
and the supernatant from each culture was used to repeat
infection every 24 h, for a total of 12 passages of in vitro
evolution (Figure 4A). We collected total RNA at passage
0, 6 and 12 of the time course experiment and performed
targeted RT and sequencing of the mutated domains. After
just six passages we observed the appearance of two inde-
pendent mutations (A1667C and U1668C) within the motif
from segment 4 (Figure 4B). These mutants are expected to
revert the mutant motif to a WT-like structure by stabiliz-
ing the bottom stem, one by restoring the base-pair between
positions 1610–1667 that we previously abolished by tar-
geted mutagenesis, and the other by transforming the G:U
wobble pair between positions 1609–1668 into a canonical
GC pair, hence increasing the motif ’s stability by >2 kcal
mol−1. This acquired U1668C mutation results in a change
in the encoded amino acid from a Serine to a Proline. No-
tably, multiple sequence alignment of all IAV subtypes re-
vealed that nearly any amino acid can occur at this posi-
tion, although with different frequencies, and that a Proline
naturally occurs in at least 2 IAV strains (Influenza A virus
(A/goose/Guangdong/G3143/2014(H6)) and Influenza A
virus (A/swine/QC/7780/2009(H1N1))). Altogether, our
analysis suggests that stabilizing this RNA structural mo-
tif has higher relevance for IAV fitness than preserving the
underlying amino acid sequence. Accordingly, multi-cycle
growth kinetics assay performed for passage 12 IAVs con-
firmed rescue of the WT phenotype for this spontaneous
segment 4 revertant (Figure 4C). Nonetheless, reversion to
the WT sequence (A1667C) appears to have a competitive
advantage over the U1668C mutation, as demonstrated by
the disappearance of the latter in replicates 2 and 3 already
at passage 12, and in replicate 1 at passage 22 (data not
shown).
DISCUSSION
The importance of RNA structure as a regulatory key
player in the complex cellular environment has experienced
increasing appreciation during recent years. This entailed
fast method development (e.g. SHAPE-seq (57), RING-
MaP (22), SHAPE-MaP (21), DMS-MaPseq (18), LASER-
seq (58)), hence providing important insights into the bi-
ological role of RNA structure (23–25). The first genome-
wide RNA structure model was resolved for HIV-1 in 2009
(26) and recently, RNA-RNA interactions of Zika virus
were mapped in vivo (20). Also IAV RNA secondary struc-
ture has been in the focus of attention (28–40). However,
no in vivo data for IAV mRNAs were available to date and
the only genome-wide in vivo structure model for any virus
available was published only recently for Zika virus (20).
We here introduced RAPiD-MaPseq, a fast and reli-
able approach that enables the targeted querying of long
and low abundance RNAs with high precision and accu-
racy. As COMRADES (20), RAPiD-MaPseq relies on the
high affinity of biotin and streptavidin, although COM-
RADES exploits direct coupling of biotin to the probing
agent whereas RAPiD-MaPseq uses biotinylated oligonu-
cleotides to enrich specific RNAs following DMS treat-
ment. This has the advantage of allowing also RNAs with
very low abundance to be structurally interrogated, while
the sequencing depth of those RNAs is usually too low to
yield informative results in the context of a transcriptome-
wide experiment. By applying RAPiD-MaPseq to living
cells infected with IAV, we here define for the first time in
vivo, as well as in vitro, IAV mRNA secondary structures.
Although binding of NP packaging proteins to both vR-
NAs and cRNAs largely inhibits the formation of RNA sec-
ondary structures (59,60), we cannot completely rule out
the possibility that some structural domains we have here
described might protrude from the NP-cRNA complex; a
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Figure 4. Spontaneous reversion of segment 4mutant IAV. (A) Schematic of the in vitro IAV evolution experiment. (B) Selected structural motif for segment
4. Bases that were altered by targeted mutagenesis are indicated in red. Spontaneous mutations appearing during the time course of in vitro evolution are
indicated in green. (C) IAV multi-cycle growth kinetics. MDCK cell monolayers were infected with WT or mutant 4 IAVs (either from passage 0 or 12 of
the in vitro evolution experiment, replicate #1) at a MOI of 10−4. At 14 h post-infection, supernatants were harvested and viral titers determined by plaque
assay. P-values are given by Welch’s t-test statistics. Error bars correspond to SEs from 3 biological replicates.
possibility that is supported by recent works showing that
vRNAs-bound NP proteins are non-uniformly distributed
(6,61,62).
IAVmRNAs appear to be mostly unfolded in living cells,
analogously to what has been previously shown for mam-
malian mRNAs (12), oppositely to the tight conformation
the IAV transcriptome adopts under in vitro conditions.
Importantly, this is reflected by the number of literature-
available structures that are supported by our data (∼70%
for in vitro, ∼50% for in vivo), as available structures were
mostly determined under in vitro conditions. However, al-
though IAV mRNAs are mostly unfolded in vivo, we here
identified several new in vivo stably-folded IAV mRNA
structural motifs. After ranking these motifs according to
their occurrence probability under both in vivo and in vitro
conditions and to their conservation, we selected the top-
scoring structure for each IAV mRNA segment and vali-
dated its biological importance by disrupting them through
targeted mutagenesis. A similar approach was used by (41)
to assess the effect of disrupting three structural motifs
in the context of splicing of segments 7 (M1/M2) and 8
(NS1/NEP). The work presented herein extends this to the
whole IAVmRNAtranscriptome and targets structuralmo-
tifs that were discovered de novo in the context of IAV infec-
tion in living host cells. Importantly, only disruption of a
segment 7 IAV mRNA structural motif did not have any
impact on the fitness of the virus, whereas all other tested
motifs resulted in a striking attenuation of IAV replication.
Concerning the biological role of theRNA structuralmo-
tifs we have here identified, at least three scenarios can be
hypothesized. First, these structural elements could influ-
ence half-lives of the respective mRNAs. Accordingly, it has
been previously shown that stem-loop structures close to the
3′ end can increase transcript half-lives (63) and that, gener-
ally, transcript stability and the presence of RNA secondary
structures are interrelated (64,65).
Second, these structures might be involved in transla-
tional regulation. RNA structure is known to promote and
regulate ribosome pausing (65–67). This mechanism has
been previously proposed to be necessary to ensure proper
co-translational folding of certain protein domains in the
context of HIV-1 protein synthesis (26). Furthermore, the
different distribution of locally-stable RNA structural ele-
ments along different IAV mRNAs might indirectly regu-
late the proportion of synthesized viral proteins as a conse-
quence of different translation efficiencies.
A third possibility is that these structures might serve as
docking platforms for specific protein interactors, or as de-
coys to sequester factors of the host’s antiviral response in
a similar fashion to certain viral proteins (68).
Although the mortality rate of Influenza has substan-
tially decreased during the last century, according toWHO,
1 out of 1000 people who contract flu are estimated to die.
Thus, the control of Influenza infections still poses ma-
jor challenges. The current antiviral arsenal against IAV
is in fact limited to three classes of FDA-licensed drugs:
matrix protein inhibitors, neuraminidase inhibitors (NAIs)
and the recently approved cap-dependent endonuclease in-
hibitors. Among the first, amantadine and rimantadine pre-
vent the viral uncoating in endosomes by interfering with
M2 ion channel-mediated acidification. However, nearly all
the circulating IAV H1N1 and H3N2 viruses have evolved
resistance to these drugs (69). NAIs, such as oseltamivir
and zanamivir, on the other hand, inhibit the release of
IAV particles from infected cells, and currently represent
the first-line therapy against influenza infections. Despite
their efficacy, however, the number of circulating NAI-
resistant viruses has greatly increased in the past few years
(70). Lastly, baloxavir is a selective inhibitor of the cap-
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dependent endonuclease activity of the polymerase acidic
protein PA, that halts the cap snatching and therefore pre-
vents viral mRNA synthesis (71,72). However, resistance to
baloxavir has been reported already during phase II and III
clinical trials (71). Given these facts, the development of
novel anti-influenza agents that are effective against anti-
genically different viruses is urgently needed.
Targeting conserved IAV mRNA structural features rep-
resents an intriguing new possibility for the development
of small molecule drugs. Indeed, the interest in the field
is rapidly growing and entailing increased research and
method development for high-throughput screenings of
small molecules targeting RNAs (73,74). Biologically im-
portant RNA structures are often more conserved than
the underlying amino acid sequence. Thus, targeting highly
conserved viral RNA structures might lead to design and
development of antiviral molecules less prone to rapidly be-
come ineffective.
The in vivo transcriptome-wide map of IAV mRNA sec-
ondary structures presented here offers a plethora of novel
in vivo-relevant IAV mRNA structural motifs, thus provid-
ing the unique opportunity to screen for therapeutically-
active small molecule binders, similarly to what has been
recently proposed for the Hepatitis C virus (HCV) (74).
Moreover, extensive differences revealed by our compara-
tive analysis of IAV mRNA structures under in vivo and
in vitro conditions underline the importance of in vivo
RNA structure determination. RAPiD-MaPseq is a deci-
sive method for studying any RNA virus in its native in vivo
conformation, including viruses that pose serious threats to
public health.
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